Chemotherapy/immunotherapy combo shows promise for first-line treatment of mesothelioma

June 11, 2020

Inoperable malignant pleural mesothelioma, is a rare and aggressive cancer of the protective lining of the lungs, or pleura, often caused by exposure to asbestos. At the annual meeting of the American Society of Clinical Oncology (ASCO), held virtually from May 29-31, 2020, a researcher from the Johns Hopkins Kimmel Cancer Center
According to

Patients received six treatments of the combination therapy every three weeks, followed by treatment with durvalumab alone, for up to one year in total. The chemo-immunotherapy combination improved overall survival to 20.4 months from the historically expected survival of 12 months with chemotherapy alone. This is the first study to show survival times exceeding 20 months for patients with inoperable mesothelioma. The treatment was well-tolerated overall, with no unexpected side effects reported.

"Inflammation is key to the development of pleural mesothelioma and, as such, it represents a key target for immunotherapy. This, in addition to earlier studies that showed promising results using the same immunotherapy drug in previously treated cases, led us to study the combination," says Forde. "Because of the promising results, we are in the process of starting a phase 3 study to confirm the benefit of this approach." This study will begin accruing patients across the United States and Australia in late 2020.

The researchers studied tissue samples from patients who received the combination therapy and found that it prevented a protein called PD-L1 from forming a "protective armor" around cancer cells. The researchers say that's because immunotherapies known as checkpoint blockers, such as durvalumab, act against PD-L1 and therefore, disrupt a cancer cell's ability to avoid detection and destruction by immune cells.
-end-


Johns Hopkins Medicine

Related Asbestos Articles from Brightsurf:

Trial targets deadly lung cancer
With more than 650 Australians diagnosed with malignant mesothelioma last year, Flinders University is leading new research to discover alternatives to chemotherapy and even prevent deaths by early detection in future.

Tiny golden bullets could help tackle asbestos-related cancers
Gold nanotubes - tiny hollow cylinders one thousandth the width of a human hair - could be used to treat mesothelioma, a type of cancer caused by exposure to asbestos, according to a team of researchers at the Universities of Cambridge and Leeds.

Two drugs used in combination prove to be effective against most aggressive asbestos cancer in mice
Currently, there are few effective treatments for malignant mesothelioma, although it has been decades since it was found that the major risk factor is exposure to asbestos.

Asbestosis toxicity study identifies potential of novel mineral treatment
Scientists investigating the ability of a micronized mineral compound to counteract the carcinogenic effects of mesothelioma and asbestosis, say results from both cell culture and animal model studies are very promising, warranting further investigation, including the commencement of clinical trials.

Free lung cancer screening program builds valuable relationships with patients
A free, simple screening for lung cancer can save a patient money, while building a healthy relationship for any medical needs they may have in the future.

Subset of carbon nanotubes poses cancer risk similar to asbestos in mice
Researchers have shown for the first time in mice that long and thin nanomaterials called carbon nanotubes may have the same carcinogenic effect as asbestos: they can induce the formation of mesothelioma.

Landmark asbestos study published in The Lancet Public Health
A landmark study from The Australian National University into the health impacts of living in a house with loose-fill asbestos insulation has been published in the international journal The Lancet Public Health.

Rare genetic cause of peritoneal mesothelioma points to targeted therapy
BWH investigators have uncovered a new genetic cause of mesothelioma: a genetic rearrangement in the ALK gene, observed in three patients with peritoneal mesothelioma.

Researchers raise health concerns about off-road vehicles and inhalation of asbestos
Preventing injuries may not be the only reason children shouldn't use off-road vehicles (ORVs).

Early research suggests first immunotherapy for mesothelioma on the horizon
Malignant pleural mesothelioma or MPM is a rare cancer, but its incidence has been rising.

Read More: Asbestos News and Asbestos Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.